Role of cyclic AMP in the actions of cannabinoid receptors.
S R Childers, S A Deadwyler
Biochemical Pharmacology September 27, 1996 DOI: 10.1016/0006-2952(96)00419-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | Argues that cannabinoids act principally through G-protein-coupled receptors, with G-protein activation as the initiating signaling step, and that inhibition of adenylyl cyclase is only one of several coupled effectors. Proposes that this inhibition contributes to cannabinoid functions including modulation of a voltage-dependent K+ channel ("A" current) in the hippocampus, and may also produce long-term gene-expression changes and inhibit anandamide synthesis. |
Abstract
Cannabinoids, including delta 9-tetrahydrocannabinol (THC), bind to receptors that couple to Gi/o-proteins and inhibit adenylyl cyclase. However, like other G-protein-coupled receptors, cannabinoid receptors are also coupled to other effector systems. This review examines the characteristics of the cannabinoid-G-protein-adenylyl cyclase system, and explores the role of cyclic AMP in mediating effects of these drugs. Several conclusions emerge from this research. First, the principal actions of cannabinoids are mediated through G-protein-coupled receptors, and the intracellular signaling mechanism that initiates cellular response of cannabinoids is activation of G-proteins. Second, cannabinoid-inhibited adenylyl cyclase is only one of several different effectors coupled to these receptors, and different effectors may be used for different types of responses. Third, cannabinoid inhibition of adenylyl cyclase plays an important role in several aspects of cannabinoid function, including modulating conductance at a voltage-dependent K+ channel ("A" current) in the hippocampus, thus providing an effective rationale for behavioral effects of cannabinoids mediated in this region. Other functions of this system may include production of long-term changes in gene expression by inhibition of cyclic AMP response elements on strategic genes, and inhibition of anandamide synthesis, thus mediating some of the long-term effects of cannabinoids on neuronal function.
Citations in the library
Cited by 3
- Cannabinoids and Vanilloids in Schizophrenia: Neurophysiological Evidence and Directions for Basic Research Frontiers in Pharmacology June 21, 2017
- Endocannabinoid Signaling and Long-term Synaptic Plasticity Annual Review of Physiology February 12, 2009
- The effects of cannabinoids on the brain. Progress in Neurobiology July 1999
Cites 8
- Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride]. Biochemical Pharmacology March 8, 1996
- Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. Journal of Medicinal Chemistry January 19, 1996
- Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochemical Pharmacology September 15, 1994
- Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids. Journal of Pharmacology and Experimental Therapeutics March 1, 1993
- Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proceedings of the National Academy of Sciences of the United States of America May 1, 1992
and 3 more in the library